HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,173,693 | -15.7% | 213,971 | -20.4% | 0.02% | -19.0% |
| Q2 2023 | $9,696,734 | -8.0% | 268,831 | -2.6% | 0.02% | -19.2% |
| Q1 2023 | $10,545,366 | +201.2% | 276,129 | +348.7% | 0.03% | +160.0% |
| Q4 2022 | $3,501,455 | -25.8% | 61,537 | -48.5% | 0.01% | -28.6% |
| Q3 2022 | $4,721,000 | +1562.3% | 119,406 | +1588.9% | 0.01% | +1300.0% |
| Q4 2021 | $284,000 | -95.5% | 7,070 | -95.5% | 0.00% | -96.3% |
| Q3 2021 | $6,368,000 | -47.0% | 156,530 | -40.9% | 0.03% | -52.6% |
| Q2 2021 | $12,026,000 | +790.2% | 264,828 | +736.9% | 0.06% | +612.5% |
| Q4 2020 | $1,351,000 | +72.3% | 31,643 | -20.9% | 0.01% | +166.7% |
| Q1 2018 | $784,000 | +512.5% | 40,005 | +196.3% | 0.00% | +200.0% |
| Q1 2016 | $128,000 | -98.3% | 13,500 | -98.2% | 0.00% | -98.5% |
| Q4 2014 | $7,321,000 | – | 758,645 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |